NCT06036797View on ClinicalTrials.gov

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 17, 2023

Primary Completion Date

October 17, 2023

Study Completion Date

October 17, 2023

Conditions
AnalgesiaLabor Pain
Interventions
DRUG

Hydromorphone

For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone

DRUG

Sufentanil

For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil

DRUG

Ropivacaine

0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Trial Locations (1)

430000

RECRUITING

Maternal and Child Health Hospital of Hubei Province, Wuhan

All Listed Sponsors
lead

Maternal and Child Health Hospital of Hubei Province

OTHER